IMMP

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. The Company has three clinical and one pre-clinical LAG-3-related product candidates under development, including two antibodies for modulating immune responses in cancer and autoimmunity. Its lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), an antigen-presenting cell (APC) activator, which is being investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) for various cancer indications, including IMP761, which is preclinical immunotherapy for autoimmune disease; LAG525 or leramilimab (IMP701), which is immunotherapy for solid tumors, blood cancer and breast cancer, and GSK‘781 (IMP731), which is immunotherapy in autoimmune diseases. Its subsidiaries include Immutep USA Inc, Immutep GmbH, Immutep Australia Pty Ltd and Immutep S.A.S.